A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy

Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F; VISIONARY Study Group

2022
Current Medical Research and Opinion

View publication

Therapeutic Area

Glaucoma
Categories

Post-Approval studies/RWE

Affiliations

Tutkimusz Ltd., Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Department of Ophthalmology, Instituto Oftalmologico Gomez-Ulla, Santiago de Compostela, Galicia, Spain; Department of Ophthalmology, LLC Vzglyad, Leningradskaya, Chita, Russia; Medical Affairs, Santen SA, Geneva, Switzerland; Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy

Related Publications

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain

Canut MI, García-Feijoo J, Larrosa-Poves JM, López-López F, Pazos M, Espinoza-Cámac N, Oyagüez I, Del Rio T, Rodríguez M.

View all Glaucoma publications